• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Embecta seeks high growth with low tech

cafead

Administrator
Staff member
  • cafead   Apr 06, 2022 at 11:52: AM
via Until last week Becton Dickinson was the world’s biggest provider of insulin syringes and pen injectors. On Friday it spun out Embecta, which now assumes that mantle. Embecta has ambitions to grow its injector business, but also to diversify away from its low-tech core, and is willing to spend lavishly to do so.

article source